Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6102-6112

  Mendonca, Janet ^a   Sharma, Anup ^a   Kim, Hae Soo ^a   Hammers, Hans ^a   Meeker, Alan ^a   Marzo, Angelo De ^a   Carducci, Michael ^a   Kauffman, Michael ^b   Shacham, Sharon ^b   Kachhap, Sushant ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Karyopharm Therapeutics   (United States)

Author keywords

CRM1; Nucleocytoplasmic transport; Prostate cancer; SINE inhibitors; XPO 1

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; EXPORTIN 1; GREEN FLUORESCENT PROTEIN; KPT 185; KPT 251; KPT 301; PROTEASOME; PROTEIN P53; SELECTIVE INHIBITOR OF NUCLEAR EXPORT; SELINEXOR; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL NUCLEUS; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; DU 145 CELL LINE; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; PC3 CELL LINE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ACTIVE TRANSPORT; DRUG EFFECTS; GENETIC TRANSFECTION; METABOLISM; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS; TRANSFECTION;

EID: 84906238637     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2174     Document Type: Article

References (39)

1. Mellman I and Nelson WJ. Coordinated protein sorting, targeting and distribution in polarized cells. Nat Rev Mol Cell Biol. 2008; 9: 833-45.
2. Clarke PR and Zhang C. Spatial and temporal coordination of mitosis by Ran GTPase. Nat Rev Mol Cell Biol. 2008; 9: 464-77.
3. Lim RY, Fahrenkrog B. The nuclear pore complex up close. Curr Opin Cell Biol. 2006; 18: 342-7.
4. Kau TR, Way JC, Silver PA. Nuclear transport, cancer: from mechanism to intervention. Nat Rev Cancer. 2004; 4: 106-17.
5. Nigg EA. Nucleocytoplasmic transport: signals, mechanisms, regulation. Nature. 1997; 386: 779-87.
6. Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M and Nishida E. XPO 1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 1997; 390: 308-11.
7. Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, Gu H, Chook YM. Structural basis for leucine-rich nuclear export signal recognition by XPO 1. Nature. 2009; 458: 1136-41.
8. Izaurralde E, Kutay U, von Kobbe C, Mattaj IW, Gorlich D. The asymmetric distribution of the constituents of the Ran system is essential for transport into and out of the nucleus. Embo J. 1997; 16: 6535-47.
9. Gorlich D, Pante N, Kutay U, Aebi U and Bischoff FR. Identification of different roles for RanGDP and RanGTP in nuclear protein import. Embo J. 1996; 15: 5584-94.
10. Gorlich D and Kutay U. Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol. 1999; 15: 607-60.
11. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH and Sun YJ. Prognostic value of XPO 1 in pancreas cancer. Clin Invest Med. 2009; 32: E315.
12. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD. The Karyopherin proteins, XPO 1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 2009; 124: 1829-40.
13. Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, Sehouli J, Dietel M and Denkert C. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008; 112: 1733-43.
14. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, Ford RJ, Pham LV. Novel selective inhibitors of nuclear export XPO 1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013; 41: 67-78 e4.
15. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of XPO 1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 2009; 65: 153-9; discussion 159-60.
16. Turner JG and Sullivan DM. XPO 1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008; 15: 2648-55.
17. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318: 1108-13.
18. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, et al. The mutational landscape of lethal castrationresistant prostate cancer. Nature. 2012; 487: 239-43.
19. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M, Horinouchi S. Leptomycin B inactivates XPO 1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A. 1999; 96: 9112-7.
20. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996; 74: 648-9.
21. Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, Chook YM. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by XPO 1. Proc Natl Acad Sci U S A. 2013; 110: 1303-8.
22. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A. KPT-330 inhibitor of XPO 1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013; 161: 117-27.
23. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R. Preclinical activity of a novel XPO 1 inhibitor in acute myeloid leukemia. Blood. 2012; 120: 1765-73.
24. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, et al. Selective inhibitors of nuclear export show that XPO 1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012; 120: 4621-34.
25. Love DC, Sweitzer TD, Hanover JA. Reconstitution of HIV-1 rev nuclear export: independent requirements for nuclear import, export. Proc Natl Acad Sci U S A. 1998; 95: 10608-13.
26. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012; 44: 685-9.
27. Shukla S, Bhaskaran N, Maclennan GT, Gupta S. Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice. Prostate. 2013; 73: 1507-17.
28. Wang Y, Kreisberg JI and Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/ Akt pathway in prostate cancer. Curr Cancer Drug Targets. 2007; 7: 591-604.
29. Vogt PK, Jiang H, Aoki M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle. 2005; 4: 908-13.
30. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, et al. The mutational landscape of lethal castrationresistant prostate cancer. Nature. 2012; 487: 239-43.
31. Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H, Luo J, Visakorpi T and Rubin MA. The mutational landscape of prostate cancer. Eur Urol. 2013; 64: 567-76.
32. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol. 1998; 18: 7288-93.
33. Hu H, Jiang C, Li G, Lu J. PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis. 2005; 26: 1374-81.
34. Tanaka T, Halicka HD, Traganos F, Seiter K, Darzynkiewicz Z. Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase. Cell Cycle. 2007; 6: 371-6.
35. Conti E, Izaurralde E. Nucleocytoplasmic transport enters the atomic age. Curr Opin Cell Biol. 2001; 13: 310-9.
36. Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J and Chook YM. Nuclear export inhibition through covalent conjugation, hydrolysis of Leptomycin B by XPO 1. Proc Natl Acad Sci U S A. 2013; 110: 1303-8.
37. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R. The histone deacetylase inhibitor NVPLAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ ZK222584. Cancer Res. 2004; 64: 6626-34.
38. Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M, Shabbeer S, Mendonca J, Deangelis J, Marchionni L, Lin J, Hoti N, Nortier JW, DeWeese TL, Hammers H, Carducci MA. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One. 2010; 5: e11208.
39. Wissing MD, Mendonca J, Kortenhorst MS, Kaelber NS, Gonzalez M, Kim E, Hammers H, van Diest PJ, Carducci MA, Kachhap SK. Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent, in combination with histone deacetylase inhibitors. FASEB J. 2013; 27: 4279-93.